Abstract | OBJECTIVE: To investigate whether the maternal serum concentration of placental protein 13 (PP13) is altered in chromosomally abnormal pregnancies and to examine the potential value of this placental protein in screening for aneuploidies at 11-13 weeks. METHODS: RESULTS: CONCLUSION: The measurement of maternal serum PP13 at 11-13 weeks does not improve the performance of screening for aneuploidies achieved by current algorithms.
|
Authors | Ranjit Akolekar, José María Pérez Penco, Evdoxia Skyfta, Jesús Rodríguez Calvo, Kypros H Nicolaides |
Journal | Fetal diagnosis and therapy
(Fetal Diagn Ther)
Vol. 27
Issue 2
Pg. 72-7
( 2010)
ISSN: 1421-9964 [Electronic] Switzerland |
PMID | 20332643
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | 2010 S. Karger AG, Basel. |
Chemical References |
- Chorionic Gonadotropin, beta Subunit, Human
- Galectins
- LGALS13 protein, human
- Pregnancy Proteins
- Pregnancy-Associated Plasma Protein-A
|
Topics |
- Adult
- Aneuploidy
- Case-Control Studies
- Chorionic Gonadotropin, beta Subunit, Human
(blood)
- Chromosome Aberrations
- Chromosomes, Human, Pair 13
(genetics)
- Chromosomes, Human, Pair 18
(genetics)
- Down Syndrome
(blood)
- Female
- Galectins
(blood)
- Gestational Age
- Humans
- Nuchal Translucency Measurement
- Pregnancy
- Pregnancy Proteins
(blood)
- Pregnancy-Associated Plasma Protein-A
(analysis)
- Prenatal Diagnosis
(methods)
- Trisomy
(diagnosis)
- Turner Syndrome
(blood)
|